P.Y., M.T.). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-To evaluate direct versus indirect monocyte chemoattractant protein (MCP)-1/CCR2 signaling and to identify the cellular producers and effectors for MCP-1 during neointimal hyperplasia (NIH) development in vein grafts. Methods and Results-Genomic analysis revealed an overrepresentation of 13 inflammatory pathways in wild-type vein grafts compared with CCR2 knockout vein grafts. Further investigation with various vein graft-host combinations of MCP-1-and CCR2-deficient mice was used to modify the genotype of cells both inside (graft-intrinsic group) and outside (graft-extrinsic group) the vein wall. CCR2 deficiency inhibited NIH only when present in cells extrinsic to the graft wall, and MCP-1 deficiency required its effectiveness in cells both intrinsic and extrinsic to the graft wall to suppress NIH. Deletion of either MCP-1 or CCR2 was equally effective in inhibiting NIH. CCR2 deficiency in the predominant neointimal cell population had no impact on NIH. Direct MCP-1 stimulation of primary neointimal smooth muscle cells had minimal influence on cell proliferation and matrix turnover, confirming an indirect mechanism of action. Conclusion-MCP-1/CCR2 axis accelerates NIH via its signaling in graft-extrinsic cells, particularly circulating inflammatory cells, with cells both intrinsic and extrinsic to the graft wall being critical MCP-1 producers. These findings underscore the importance of systemic treatment for anti-MCP-1/CCR2 therapies. (Arterioscler Thromb Vasc Biol. 2012;32:2418-2426.)
N eointimal hyperplasia (NIH) is the primary culprit that causes early vein graft (VG) failure. A large body of evidence has demonstrated circulating inflammatory cells and, in particular, monocytes as the critical drivers for this pathology. 1 In a freshly created VG, monocytes follow the chemokine gradient established by the local inflammatory cascades, homing to the injured vessel wall. Although various mediators may be involved in this process and marked functional redundancy may exist among them, monocyte chemoattractant protein (MCP)-1 has been shown to be critical for monocyte trafficking. 2 Underscoring this concept, several groups, including our laboratory, have observed that blocking MCP-1/CCR2 signaling reduces monocyte content and attenuates neointimal growth in VGs [3] [4] [5] [6] and injured arteries. 7, 8 MCP-1/CCR2 signaling has traditionally been considered to function exclusively in the regulation of monocyte biology. 2 However, this long-standing paradigm has been challenged by recent studies showing that smooth muscle cells are able to respond to MCP-1 stimulation with enhanced migration and upregulation of the proinflammatory genes. 5, [9] [10] [11] Although these studies suggest a novel mechanism that vascular cells may serve as direct MCP-1 effectors, translating these observations to the complex events, such as VG failure, has raised a critical issue concerning the precise cellular elements that drive NIH. This issue is further complicated by the dynamic alteration in the neointimal cell population, where the composition varies temporally because of the constant influx and outflux of cells from local (eg, the graft wall) and remote (eg, bone marrow, circulation, and perivascular tissue) locations. 12, 13 MCP-1 is a secreted and soluble protein. 7 Once produced, it functions in an autocrine as well as paracrine manner. Although the location of MCP-1 production is not essential to understand the general tissue response, it is critical for targeted anti-MCP-1 therapy. During NIH development, the composition and the relative proportion of various cell types are in constant flux. Targeted therapy requires both identification of the MCP-1 producers and the temporal patterns during which these cells are most active. For example, monocytes secrete a large amount of MCP-1 in the VG wall, 7, 14 yet are recruited primarily in early remodeling phases, with few cells present after resolution of the acute inflammation. Vascular cells, such as smooth muscle cells (SMCs) and endothelial cells, then take over the task to maintain a persistent MCP-1 production in the neointimal lesion. 3, 5, 14 This temporal switch in the predominant MCP-1 producer has raised uncertainties as to the most critical cell type that propagates the hyperplastic response. Clarification of this issue will not only provide mechanistic insights into the MCP-1/CCR2 signaling biology in the VG wall but also direct how MCP-1 may be targeted to inhibit NIH.
A well-known phenomenon for chemokine signaling is the promiscuous ligand-receptor recognition. In addition to MCP-1, other MCPs (such as MCP-2 to 5 and 16) 15, 16 can also activate CCR2 at physiological concentrations. This ligand redundancy has questioned the direct linkage between MCP-1 and CCR2 and whether MCP-1 production and CCR2 receptor expression is the dominant driver for neointimal thickening.
Built on the fundamentals outlined above, the current study sought to resolve these issues and elucidate the mechanisms, whereby the MCP-1/CCR2 axis regulates NIH development in VGs via (1) identifying the cellular producers and effectors for MCP-1, (2) determining the relative importance of promiscuous CCR2 binding to MCPs other than MCP-1, and (3) evaluating the in vivo significance of direct MCP-1/CCR2 signaling in vascular cells on growth of the neointima.
Methods

Animal Model of the VG
This study conforms to the American Physiological Society's Guiding Principles for the Care and Use of Vertebrate Animals and the Guide for the Care and Use of Laboratory Animals (National Research Council, Revised 2010). Murine VGs were created by placing an inferior vena cava (IVC) from a donor animal to the common carotid artery of a host animal. This procedure provides the opportunity to vary the genotype of cells inside the vein (graft-intrinsic cell group), as well as those from locations outside the vein wall (graft-extrinsic cell group). The external branch of the common carotid artery was ligated to reduce blood flow through the VG. Details of this technique have been described in our previous reports. 3, 17 All mice used in this study were adult (9-to 11-week-old) males. MCP-1 null (MCP-1 −/− ), CCR2 null (CCR2 −/− ), chicken actin promoter-enhanced green fluorescent protein (EGFP) (a ubiquitous EGFP reporter and abbreviated as EGFP + in the rest of the text), and the wild-type (WT) control (C57BL/6) mice were purchased from Jackson Laboratory. CCR2 −/− EGFP + mice were produced in our institution by crossing CCR2 −/− with EGFP + strains. The genotype of the implanted VG and recipient host will be presented in the form of vein→host in this report. Grafting a WT IVC to an EGFP host, for instance, will be noted as WT→EGFP + .
Microarray Gene Expression
The global gene expression in VGs with (n=5) or without (n=5) CCR2 was profiled using Agilent mouse genomic array chip, with age-matched WT nonimplanted IVCs (n=5) serving as a baseline reference. Samples were collected 7 days after implantation, with this time point chosen based on our previous investigation of the temporal pattern of gene expression and identification of the dominant response to injury (unpublished data).
Total RNA was extracted from VGs and IVCs with RNeasy Mini columns (Qiagen, Valencia, CA) and cleaned with DNase I. After reverse transcription of RNA to cDNA, cRNA was generated with 20 μg cDNA template and labeled with Cy3 and Cy5 for reference (pooled IVCs) and experimental samples (VGs), respectively. Equal amount of labeled cRNA (100 ng) derived from each VG and the reference was mixed, fragmented, and hybridized to microarray chips (Agilent) at 60°C for 17 hours. After acquiring the raw data by scanning arrays with an Agilent G2505 B Scanner, corrections for both background and variations in signal intensity were performed.
The processed data were further analyzed with BRB Array Tools (http://linus.nci.nih.gov/BRB-ArrayTools.html) and FatiScan. 18 These programs apply completely different principles to their analyses, with the BRB Array Tools taking each gene as an independent variable and FatiScan considering genes functioning on a modular fashion. 18 For identification of genes differentially expressed between CCR2 −/− VGs and the WT controls, a random variance model with a nominal significance level of 0.001 was used. For FatiScan analyses, genes that passed the initial raw data process were sorted with their statistics (2-tailed Fisher exact test). KEGG pathway analysis was then performed with a partition of 30 and an adjusted P value of 0.05 (the Benjamini and Hochberg false discovery rate). 19 
Selective Deletion of MCP-1 or CCR2 in Graft-Intrinsic or Graft-Extrinsic Cell Group
VGs with and without MCP-1/CCR2 signaling in either graft-intrinsic or graft-extrinsic cells (n=9-16 per group) were created by varying the genotype of the venous conduits and host animals. The impact of MCP-1 or CCR2 signaling on neointimal thickening was evaluated separately, with the concept that deficiency in MCP-1 identifies the cellular producers whereas deficiency in CCR2 identifies cellular effectors for MCP-1. Comparison between the 2 evaluates the relative in vivo significance of the MCP-1/CCR2 axis and the promiscuous binding of CCR2 to other MCPs. Four weeks after graft implantation, surgical samples were perfusion fixed in 10% buffered formalin, paraffin embedded, histologically sectioned, and processed with Masson for the assessment of neointimal thickness. 20 Similar to what we have shown previously with rodent VG models, 3, 17 the tunica media of the vein is only 2 to 3 cell layers thick and becomes indistinguishable from the neointimal tissue 4 weeks after graft implantation. The residual media might have been included in our measurements of the neointimal thickness.
Cell Tracing
An assumption made in this experiment is that if the MCP-1/CCR2 signaling in neointimal cells contributes significantly to neointimal growth, genetic interruption of the MCP-1/CCR2 signaling in the cell group that dominates neointimal cell repopulation would attenuate neointimal thickening. To test whether it can be the graft-intrinsic or graft-extrinsic cell group, we selectively traced the destination of cells from each group with EGFP reporter. VGs with the restriction of EGFP to graft intrinsic (EGFP + →EGFP − ), extrinsic (EGFP − →EGFP + ), or both (EGFP + →EGFP + ) cell groups (n=6 for each combination) were created with WT and EGFP mice. The same experiment was repeated under conditions with and without CCR2 deficiency to examine whether the primary source of the neointimal cell population is influenced by selective CCR2 deletion. All VGs were perfusion fixed with 2% paraformaldehyde+0.2% glutaraldehyde in PBS (pH 7.4) 4 weeks after placement. Frozen sections were counterstained with propidium iodide, and EGFP-positive cells were evaluated with confocal microscopy and differential interference contrast imaging.
Immunohistochemistry Assay
Endothelium, leukocytes, and macrophages were identified by their expression of CD31 (Abcam), CD45 (R&D), and F4/80 (Serotec) and visualized with enzymatic substrate (3, 3′-diaminobenzidine) or fluorescent conjugates (Texas-Red). Re-endothelialization by host-derived cells was evaluated on cross-sections. The extent of EGFP-positive endothelial cells populating the luminal surface was measured and expressed as percent of the circumference.
Culture of the Primary Medial and Neointimal SMC
Medial SMCs were harvested from the outgrowth of aortic explants using methods described by others. 21 Neointimal tissue was selectively isolated using microsurgical dissection techniques, as we previously described. 20 Both medial and neointimal explants were cultured in DMEM plus 10% fetal bovine serum. Cell outgrowths were passaged in 2 to 3 weeks, and the purity of SMCs was evaluated using a flow cytometry-based assay for α-actin. Cultures with >95% α-actinpositive cells were expanded by 5 to 10 passages for in vitro assays.
MCP-1 Stimulation
Proliferation of the neointimal SMCs (neoSMCs) and primary medial SMCs was evaluated with bromodeoxyuridine (BrdU) incorporation and cell cycle progression in triplicate. Cells were seeded at a density of 10 000 cells/cm 2 and cultured in DMEM with 10% fetal bovine serum. On reaching 90% confluence, cells were serum deprived for 24 hours, followed by treatment with serum-free media, transforming growth factor-β1 (1 ng/mL, R&D), MCP-1 (0.1, 1.0, 10, and 100 ng/mL, GenWay), transforming growth factor-β1+MCP-1 (10 ng/mL), or serum for 24 hours. For BrdU incorporation assay, BrdU (10 µmol/L) was added to the medium 24 hours before the assay, and the amount of incorporated BrdU was quantified with a Cell Proliferation Assay kit (Roche Applied Science). For cell cycle assay, treated cells were washed with PBS, fixed with 70% ethanol, and incubated in propidium iodide (20 μg/mL), Triton X-100 (0.1%), and RNaseA (0.2 mg/mL). DNA content of the individual cells was then quantified with flow cytometry.
Real-Time Reverse Transcription Polymerase Chain Reaction
In an attempt to evaluate the impact of direct MCP-1/CCR2 signaling on matrix synthesis and degradation, we measured the expression of type I collagen (COL1A2), connective tissue growth factor (CTGF), matrix metalloproteinase (MMP)-2, and MMP-9 in neoSMCs after MCP-1 treatment. Quantitative reverse transcription polymerase chain reaction was performed following the protocol described previously. 20 The primer and probe sets applied to the assays were purchased from Applied Biosystems, with the code of Mm00483937-m1, Mm01192933-g1, Mm00439498-m1, and Mm00442991-m1 for COL1A2, CTGF, MMP-2, and MMP-9, respectively.
NanoString Assay
The nCounter GX Mouse Inflammation Kit was purchased from Nanostring Technologies (http://www.nanostring.com/). Each assay includes 179 inflammation-related genes ( Table I in the online-only Data Supplement). WT, CCR2 −/− , and MPC1 −/− VGs (n=4 for each group) were created as described above. After evaluation of the quality (Bioanalyzer, Agilent) and concentration (Nanodrop, Agilent), 100 ng of total RNA was hybridized onto the capture and reporter probes. After removal of the unbound probes, the tripartite molecules were captured by fluidics devices and imaged with nCounter Digital Analyzer. 22 Raw data were processed with nSolver analysis software version 1.0 and further analyzed with BRB Tools.
Statistical Analyses
All data are expressed as mean±SEM. Comparisons were done using ANOVA, Tukey post hoc analysis, and unpaired t test, as appropriate. P<0.05 was considered significant
Results
Inflammatory Pathways Dominate the Global Gene Expression in VGs With and Without Intact MCP-1/CCR2 Signaling
A week after graft implantation, 218 genes were differentially expressed, with the vast majority downregulated in CCR2 −/− VGs compared with WT controls ( Figure 1A ). Functional annotation clustering analysis (DAVID) at the biological process-3 level demonstrated enrichment of 3 major clusters (Table  II in the online-only Data Supplement) and 1 KEGG pathway cluster ( Table III in the online-only Data Supplement) , with a high percentage of inflammatory response pathways characterizing the difference between WT and CCR2 −/− VGs ( Figure  I in the online-only Data Supplement). This finding was further confirmed with FatiScan analyses ( Figure 1B ). Fifteen KEGG pathways were differentially expressed between WT and CCR2 −/− VGs, with the majority (13 KEGG pathways) of them overrepresented in WT VGs (red bars). Functional annotation demonstrates that all 13 pathways are well-recognized inflammatory pathways associated with innate and adaptive immune responses.
MCP-1/CCR2 Signaling in Graft-Extrinsic Cell Group Drives Neointimal Thickening
Using gene deletion, we have demonstrated that early reduction in monocyte infiltration correlates with a significant attenuation of the following neointimal thickening in CCR2-deficient VGs. 3 Although this study along with the microarray data presented above suggests that the MCP-1/CCR2 axis regulates NIH via inflammatory mechanisms driven by monocytes (indirect effects), results from other groups show that MCP-1 can regulate SMC biology by initiating the CCR2 signaling directly in SMCs. Such direct effects may also play an important role in neointimal thickening. 5, 9, 10 To address this issue, cells intrinsic or extrinsic to the VG were independently evaluated for the influence of MCP-1 and CCR2 on NIH development.
Robust NIH developed in WT VGs (Figure 2A ; WT·WT) but was attenuated in the absence of MCP-1 or CCR2 ( Figure  2A ; KO·KO). Selective deletion of MCP-1 identified both graftintrinsic and graft-extrinsic cell groups as significant MCP-1 producers in the VG wall. Although removal of MCP-1 from both cell groups significantly inhibited NIH (P=0.026), leaving its production in either group boosted the hyperplastic response to the same level as preservation of MCP-1 production in both cell groups ( Figure 2B ), indicating cells either intrinsic or extrinsic to the graft wall are able to produce sufficient MCP-1 to accelerate NIH.
Selective deletion of the MCP-1's receptor CCR2 revealed that MCP-1 producers may not necessarily be of the same cell group as MCP-1 effectors. As evidenced by the neointimal thickening in WT·WT and KO·WT groups in Figure 2C , VGs developed robust NIH as long as the CCR2 was preserved intact in graft-extrinsic cell group; otherwise, NIH was significantly inhibited, as reflected by NIH formed in WT·KO and KO·KO groups. A simultaneous removal of CCR2 from graft-intrinsic cell group had no additive effect on the hyperplastic response, regardless of the presence or absence of CCR2 in graft-extrinsic group ( Figure 2C) . These results demonstrate that cells extrinsic to the graft wall serve as essential effectors for MCP-1/CCR2 signaling during NIH development. Cells intrinsic to the graft wall, though proved to be deleterious MCP-1 producers ( Figure  2B) , do not contribute, if at all, to NIH via MCP-1 activation.
Promiscuous Recognition of Multiple MCPs by CCR2 Receptor Is Not a Significant Determinant to Eventual Neointimal Thickening
A well-known phenomenon for transgenic mice is that the resultant defects are not limited to the function of the ablated gene. The CCR2 −/− mice, for instance, suffer attenuated Th1 responses in addition to diminished monocyte trafficking. 23, 24 Using the NanoString assay, we characterized the expression profile of the inflammatory genes in VGs with and without MCP-1 or CCR2. Unsupervised clustering analysis ( Figure 3A ) clearly defined separate expression patterns in WT, MCP-1 −/− , and CCR2 −/− VGs. Notable is the pronounced difference of the CCR2 −/− VGs from their MCP-1 −/− and WT counterparts. Comparison between CCR2 −/− and MCP-1 −/− groups at a significance level of 0.01 identified that 27 genes were differentially expressed, with the majority of them upregulated after CCR2 deletion ( Figure 3B ). GO analysis assigned these genes to 2 clusters at the biological process-4, with annotations in the primary cluster demonstrating significant differences in complement activation (GO:0006956, GO:0006958), leukocytemediated immunity (GO:0002443, GO:0002449), and regulation of immune response (GO:0050778, GO:0002684) ( Figure 3C ). Despite these differences in inflammatory response and the potential that other CC chemokines (eg, MCP-2 to 5) may bind to CCR2 and play a compensatory role, neointimal thickness was similar after either MCP-1 or CCR2 deletion ( Figure 2B and 2C; P=0.42). Because CCR2 is the only functional receptor established for MCP-1, 25 these data suggest that CCR2 primarily binds to MCP-1 to proceed NIH development, and its promiscuous binding to other MCPs plays a modest role in this process.
MCP-1/CCR2 Signaling in Vascular Intrinsic Cells Holds Limited In Vivo Significance in Neointimal Thickening
Previous reports detailing the response of SMCs to MCP-1 have been conflicting. 5, 10, 26, 27 Although our data would support that direct CCR2 binding in cells intrinsic to the graft wall has limited influence on driving the hyperplastic process, this conclusion may be confounded by an extensive repopulation of the vein wall by cells recruited from locations outside the conduit. Using the EGFP model to trace cell lineage, the contribution of cells from the vein wall to the developing neointimal was evaluated. As shown in Figure 4 , all neointimal cells show a strong EGFP signal in VGs created with EGFP veins and EGFP hosts (EGFP + →EGFP + ; Figure 4A ). In sharp contrast, only a few EGFP + cells were detected in the neointimal region in VGs created by implanting WT veins to EGFP hosts (EGFP − →EGFP + ; Figure 4B ). Switching the donor-host relationship reversed the composition of the neointimal cell population, with the EGFP + cells again being the predominant group (EGFP + →EGFP − ; Figure 4C ). Similar patterns were also observed in the absence of the CCR2 receptor ( Figure 4D-4F ). Selective removal of CCR2 exhibited no significant effects on the pattern, where cells intrinsic to the VG (eg, EGFP − cells) remain dominated in the developing neointima ( Figure 6A and 6B). Taken in context of the graft morphology data ( Figure 2C ), these observations indicate that direct MCP-1/CCR2 signaling in VG-derived SMCs holds a limited importance in vivo.
MCP-1 Is Neither Mitogenic Nor Stimulatory to NeoSMCs In Vitro
To further define the pathways whereby MCP-1/CCR2 signaling drives neointimal thickening, we evaluated the effects of MCP-1 stimulation on neoSMC proliferation and gene expression. The neoSMCs treated with escalating dose of MCP-1 demonstrated no difference in BrdU incorporation compared with nontreated controls ( Figure 5A ). Further analysis of the mitogenic response using cell cycle progression analysis revealed that MCP-1 induced few (1%) of the treated cells to undergo mitosis, whereas serum stimulated 22% of the cells to enter into S phase ( Figure 5B) . A direct impact of MCP-1 on matrix metabolism was also not detected in neoSMC cultures. Although transforming growth factor-β1 stimulated significant changes in CTGF and MMP-9 expression, administration of MCP-1 did not alter the expression of CTGF, COL1A2, MMP-2, and MMP-9 in either direction ( Figure  4C) . Bioactivity of the MCP-1 applied to this experiment was verified with a membrane fluidity assay (data not shown).
CCR2 Is Not Required for Re-endothelialization of the Denuded Luminal Surface
Under fluorescent microscopy, a combination of both EGFP + and EGFP − cells lining the lumen surface was observed in both WT→CCR2 +/+ /EGFP + and WT→CCR2 −/− /EGFP + VGs (Figure 6A and 6B ). Immunohistochemistry assay for CD31, a lineage marker specific for endothelial cells, confirmed this monolayer of cells to be of endothelial origin ( Figure 6E ). On the same section that had undergone immunohistochemistry staining, the EGFP signal remained well preserved ( Figure 6D ). Confocal imaging demonstrated colocalization of the EGFP and CD31 signal on the luminal surface ( Figure 6F) , indicating a contribution of cells of host origin to endothelial repair. Quantitatively, cells of host origin covered ≈40% of the luminal surface, and this capacity was independent of the status of MCP-1/CCR2 signaling, as evidenced by the insignificant difference in the coverage attributed to host cells with or without CCR2 ( Figure 6C ). The accumulation of cells with host origin in both the neointimal and adventitial regions varied widely in WT→CCR2 +/+ /EGFP + and WT→CCR2 −/− /EGFP + VGs, and further evaluation on these regions was not performed.
Discussion
The critical role of the MCP-1/CCR2 signaling in NIH development in VGs has been clearly demonstrated in previous studies from our group and others. [3] [4] [5] In the current study, we have provided mechanistic insights into how MCP-1/ CCR2 axis regulates NIH. Our results demonstrate that: (1) an inflammatory gene signature discriminates VGs with and without MCP-1/CCR2 signaling; (2) the graft-extrinsic cell group serves as the primary effectors for MCP-1, whereas both graft-intrinsic and graft-extrinsic cell groups are critical MCP-1 producers; (3) removal of MCP-1 or the CCR2 receptor is equally efficient in inhibiting NIH; and (4) abolishing the direct MCP-1/CCR2 signaling in neoSMCs does not impact neointimal growth. These findings suggest that MCP-1 signals through CCR2 of the graft-extrinsic cell group, most likely circulating monocytes, to accelerate NIH. The direct MCP-1/ CCR2 signaling in vascular cells and the promiscuous binding of CCR2 to other MCPs hold minimal in vivo significance in MCP-1/CCR2 signaling-regulated NIH development in VGs.
We have previously demonstrated that early reduction in monocyte recruitment correlates with attenuated NIH development in CCR2-deficient VGs. 3 Consistent with this report, the current study further identified cells extrinsic to the venous conduit as the primary effectors for MCP-1. Although graftextrinsic cells are a mixed cell population that may include leukocytes and vascular cell precursors (eg, circulating progenitors and perivascular fibroblasts), 28 a major population in this group is leukocytes. Among the leukocyte population, both monocytes and neutrophils have been demonstrated as Figure 5 . Direct monocyte chemoattractant protein (MCP)-1 stimulation lacks biological effects on neointimal smooth muscle cells (neoSMCs). Mitogenic effects of the MCP-1 on primary neoSMCs are summarized in A and B, whereas its effects on the expression of genes known to regulate matrix metabolism in primary neoSMCs are shown in C. Differences among groups treated with escalating dose of MCP-1 including vehicle controls are not statistically significant for all tested parameters (1-way ANOVA). October 2012 critical drivers for NIH. 29 However, previous investigations have shown that neutrophils are generally unresponsive to MCP-1 signaling because of the absence of the CCR2 receptor in this subpopulation. 25, 30 These observations, together with the results from the current study, have led us to conclude that monocytes are the main effector for MCP-1/CCR2 signalingregulated NIH development in VGs.
Monocytes in the circulating blood comprise a heterogeneous population. Recent studies have identified 2 distinct subsets, termed inflammatory and patrolling and defined as Gr1 + CCR2 + CX3CR1 low and Gr1 − CCR2 − CX3CR1 high , respectively. 31 Once penetrated into tissue, these cells may be further polarized to M1 and M2 macrophages, with M1 specializing at inflammation and M2 functioning to maintain tissue homeostasis. 32 In addition to monocytes, other inflammatory cell lineages, such as T cells and dentritic cells, may also participate in the NIH process. 33 Although the current study suggests monocytes as the cellular effector for MCP-1/CCR2 signaling in VGs, identification of the exact subset that drives NIH remains an open question pending complete characterization and quantification of all inflammatory infiltrates in the wall. As reported by our group 3 and others, 7 inflammatory cells take different mechanisms to adhere and migrate in vessels, in part dependent on the presence of an intact endothelial monolayer. Although phenotypic characterization of the inflammatory infiltrates has been successful in the studies for atherosclerosis, 34 application of similar strategy to assay cells in the VG wall remains challenging. Specific difficulties include the preservation of lineage markers and collection of cells in a spatial-specific fashion (eg, luminal surface versus adventitia).
Several groups have reported that SMCs express CCR2 and MCP-1 can regulate SMC biology, such as proliferation 5, 9 and production of inflammatory cytokines, 11 through the direct binding of MCP-1 to its CCR2, as opposed to the resultant effects secondary to monocyte activation. Using an in vivo approach, the current study demonstrates that removal of the CCR2 receptor from the predominant neointimal cell population has no significant impact on neointimal thickening, suggesting that the in vivo significance of the direct MCP-1 simulation of vascular SMCs is of limited importance. Schepers et al 5 have reported that CCR2 antagonist inhibits NIH development in human veins cultured in a system without monocytes, which differs from our observations. Although the preexisting pathology in the normal human saphenous vein 35 may be a contributor, further studies are required to identify the differences between these ex vivo and in vivo models.
Consistent with the observations in our murine VG model, our in vitro experiments demonstrate that neoSMCs are refractory to MCP-1 stimulation. No significant changes in the proliferation or the expression of CTGF, collagen, and MMP-9 were observed after treatment of neoSMCs with various doses of MCP-1. Similar responses were also observed for medial SMCs (data not shown). Although our results from both in vitro and in vivo experiments support the concept that the direct MCP-1 regulation of SMC biology is not essential to the hyperplastic VG response, mixed results and potential controversies exist in the field. Some groups have documented stimulatory effects of MCP-1 on SMC proliferation and gene expression, 5, 9, 10 whereas others have reported that MCP-1 treatment leads to negligible or even slightly inhibitory effects on these processes. 26, 27 Inconsistency among laboratories is not uncommon and may be magnified by nonphysiological SMC cell culture parameters, such as the seeding density, quiescence, and phenotype (eg, contractile versus dedifferentiated), all of which can impact the response of SMCs to the imposed stimulant. 36, 37 Although not comprehensive, the in vivo evidence provided in this report provides important clarification of these conflicting results.
Chemokine networks possess a great deal of functional redundancy that is supported by the promiscuous ligand/ receptor recognition and overlap in intracellular signaling pathways that are inherent in the system. For example, MCP-1 binds to receptor CCR2 to regulate monocyte trafficking, but the same CCR2 signaling pathway may be activated by other MCPs, such as MCP-2 to 5. 2, 38 In addition to MCP-1, several other members, such as MCPs, IP-10, and Fractakine, 16 can guide monocytes migrating to inflammatory lesions. It seems that none of the individual members would be essential to monocyte trafficking. However, it has been demonstrated that each of these chemokine axes can induce a robust and nonoverlap in vivo output. 39 For example, mice deficient in MCP-1 or CCR2 demonstrate a dramatic reduction in monocyte content in atherosclerotic lesion. 40, 41 This functional robustness of each chemokine axis has posed a critical question as to the signaling axis that dominates NIH development in VGs. Our results demonstrate that deletion of MCP-1 or CCR2 is equally efficient in inhibiting NIH. Because CCR2 is the only receptor identified for MCP-1, 25 the equivalent MCP-1/ CCR2 effects on NIH suggest that MCP-1 acts as the primary ligand for CCR2 to drive neointimal growth, and the impact of CCR2 binding to other MCPs on this process is marginal. Vein bypass procedures offer an opportunity to treat the conduit before implantation, thus minimizing the off-target effects that would otherwise be caused by systemic interventions. Exploring this opportunity, a wide range of preclinical studies has focused on ex vivo approaches for delivery of therapeutic agents directly into the wall. [42] [43] [44] Unfortunately, expansion of these strategies into clinical trials has been unsuccessful. 45, 46 In the current study, we have identified the graft-extrinsic cell group as the primary effector for MCP-1/CCR2 signaling. This finding supports the concept that these effectors need be targeted before their arrival at the graft wall and points toward the need for systemic delivery of anti-MCP-1/CCR2 treatments. In addition, we show that cell groups either intrinsic or extrinsic to the graft wall can produce sufficient MCP-1 to accelerate NIH, indicating both cell groups should be treated when targeting MCP-1. Taken together, systemic delivery of anti-MCP-1/CCR2 is an essential component in the design of effective therapies to reduce intimal hyperplasia and improve VG survival.
NIH, although may lead to luminal narrowing or complete occlusion, is also part of the physiological adaptation that repairs the injured venous conduit. Recent observations suggest that the homing of vascular progenitors to the injured vessel is a critical component for structural stabilization and re-endothelialization of the wall. Studies in the field have identified several key molecules that may guide stem cell homing. Among them is MCP-1 that has been shown to mediate the recruitment of hematopoietic stem cells to repair the injured liver 47 and heart. 48 Using the EGFP cell tracing approach, we examined the importance of MCP-1 in repairing endothelial denudation in VGs. The results show that cells, independent of CCR2 expression, were recruited to the luminal surface and contributed to endothelial repair, suggesting that MCP-1/ CCR2 signaling is not pivotal for re-endothelialization in our model system.
Genetic tools have provided powerful approaches to isolate specific elements for detailed investigation; however, inherent flaws in these models have called for caution in interpretation of the experimental results. The CCR2 −/− strain, for instance, displays a skew from Th1 to Th2 response, 23 with decreased production of interferon-γ and monocyte/macrophage phagocytosis. 24 A reduced capacity of producing MCP-3 and 5 has also been documented for MCP-1 −/− strain. 49 In addition to these various compensatory changes, a recent study has suggested the existence of an unidentified receptor for MCP-1, 10 which further questioned the linear MCP-1/CCR2 recognition and the phenotypic similarity of the MCP-1 −/− and CCR2 −/− VGs. In the current study, we profiled the expression of inflammatory genes in WT, MCP-1 −/− , and CCR2 −/− VGs. Unsupervised cluster analysis detected significant differences among these groups, with the majority of the differentially expressed genes upregulated in CCR2 −/− VGs. Although limited to inflammatory gene set, this tubular view clearly demonstrates that the phenotype of the MCP-1 −/− VG is different from that of the CCR2 −/− VG. Although attributed partially to the promiscuous ligand/receptor recognition, this disparity may also be the result of the defects beyond the function of the target gene in these strains. Therefore, the cause-effect relationship established with these transgenic strains for the pathogenesis of diseases needs to be verified with other approaches, such as pharmaceutical intervention and small interfering RNA gene silencing.
